CRM vs ORCL: side-by-side analysis
Cross-read of CRM (Salesforce Inc.) versus ORCL (Oracle Corporation): CRM looks meaningfully undervalued at $182 versus a fair-value midpoint of $237, while ORCL appears in our peer table. Our current rating for CRM is Strong Buy.
Where CRM and ORCL sit on fair value
CRM's composite fair-value range is $172–$303 (midpoint $237), versus a current price of $182. ORCL is one of CRM's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between CRM and ORCL is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
CRM is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. ORCL, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 12.2× forward P/E with a PEG of 1.52 is not the same on CRM as it is on ORCL unless they share the same growth profile, capital intensity, and moat half-life.
CRM's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against ORCL should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: CRM looks meaningfully undervalued versus our fair-value midpoint. The full report's peer table compares CRM and ORCL directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for CRM is bound by the kill-scenarios list in Section 2; the equivalent for ORCL would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether CRM or ORCL is the better expression of the same theme.
Bottom line — CRM or ORCL?
Our rating for CRM is Strong Buy with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes ORCL. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on CRM, including the explicit peer multiples versus ORCL and the rest of the comp set, see the canonical report at /stocks/crm/analysis. For ORCL's standalone report, see /stocks/orcl/analysis.
Frequently asked questions
CRM vs ORCL: which is cheaper today?
CRM looks meaningfully undervalued at $182 versus a fair-value midpoint of $237 (range $172–$303). The peer table inside the full report compares CRM and ORCL directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is CRM a better buy than ORCL?
Our current rating for CRM is Strong Buy; we do not co-rate ORCL on this page — see ORCL's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is CRM?
Salesforce Inc. is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. ORCL's own archetype is in its own report.
What is CRM's moat score versus ORCL?
CRM's moat score is 9/10. The full moat section covers source, durability, and threat timeline; ORCL's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full CRM report for the canonical evidence.